ArticleScandinavian journal of gastroenterology2014
Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients.
Article in Scandinavian journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.Gastroenterology · 2019Guideline
- Trial
- Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.Journal of inflammation research · 2026Review
- The psychobiotic revolution: comprehending the optimistic role of gut microbiota on gut-brain axis during neurological and Gastrointestinal (GI) disorders.World journal of microbiology & biotechnology · 2025Review
- Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction.Nature reviews. Gastroenterology & hepatology · 2025Review
- Irritable Bowel Syndrome With Diarrhea in Pediatric Patients Is Associated With Type 2 and Type 9 T Cells in the Intestinal Mucosa.Cellular and molecular gastroenterology and hepatology · 2025Article
- Bifidobacterium bifidum and Bacteroides fragilis Induced Differential Immune Regulation of Enteric Glial Cells Subjected to Exogenous Inflammatory Stimulation.Inflammation · 2022Article
- Incidence of Cancer in Patients with Irritable Bowl Syndrome.Journal of clinical medicine · 2021Article
- Increased Vδ1γδT cells predominantly contributed to IL-17 production in the development of adult human post-infectious irritable bowel syndrome.BMC gastroenterology · 2021Article
- Post-infection Irritable Bowel Syndrome.Gastroenterology clinics of North America · 2021Review
- Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body.Frontiers in immunology · 2021Review
- Human Leukocyte Antigen (HLA) Haplotype Does Not Influence the Inflammatory Pattern of Duodenal Lymphocytosis Linked to Irritable Bowel Syndrome.Medicina (Kaunas, Lithuania) · 2020Article
- The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy.Frontiers in microbiology · 2019Review
- Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects.Scientific reports · 2018Article
- Close association between intestinal microbiota and irritable bowel syndrome.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Review
- Post-Infectious Irritable Bowel Syndrome.Current gastroenterology reports · 2017Review
- Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?Annals of gastroenterology · 2017Review
- Irritable bowel syndrome, the microbiota and the gut-brain axis.Gut microbes · 2016Review
- Mechanism-Oriented Therapy of Irritable Bowel Syndrome.Advances in therapy · 2016Review
- Giardia duodenalis induces paracellular bacterial translocation and causes postinfectious visceral hypersensitivity.American journal of physiology. Gastrointestinal and liver physiology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) is characterized by chronic abdominal symptoms such as pain, discomfort, and altered bowel habits. A subset of IBS patients, denoted as post-infectious IBS (PI-IBS) patients, develop symptoms after an enteric infection. Distinct abnormalities in the gut mucosa, including mucosal inflammation, have been proposed to contribute to or be the cause of PI-IBS. This study investigated lymphocyte subsets in PI-IBS patients compared to healthy controls. MATERIALS AND
methodsTen PI-IBS patients and nine healthy controls participated. All PI-IBS patients met the Rome III diagnostic criteria for IBS and reported sustained symptoms at least 1 year after an episode of acute gastroenteritis. Intraepithelial lymphocytes and lamina propria lymphocytes (LPLs), isolated from mucosal tissue samples, were stained and analyzed for a comprehensive set of cell markers using flow cytometry.
resultsThe number of LPLs in PI-IBS was significantly increased compared to those in healthy controls (p < 0.05). PI-IBS patients showed significantly increased proportions of CD45RO(+) CD4(+) activated/memory T cells (p < 0.05) and double-positive CD4(+) CD8(+) cells (p < 0.05), respectively, in the lamina propria. The number of CD19(+) LPLs was decreased in PI-IBS patients compared to healthy controls (p < 0.001).
conclusionThis study presents new evidence that PI-IBS is associated with a sustained aberrant mucosal immune response and support future studies of anti-inflammatory or immune-modulating treatments in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.